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Abstract. Dengue infection burden has been predicted increase three times greater recently. Severe dengue 
infection associated with the high generation of inflammatory cytokines leads to vascular endothelial 
instability. Hence, the current study aim to evaluate the level of TNF-α among travellers infected with 
DENV in Bali. An observational prospective study has been conducted on travellers presenting with dengue 
symptoms who admitted at Kasih Ibu Hospital Bali in 2017. Majority of the sample was female (61%) 
which median (range) age was 29 (15.4-73.1) years old.  The median (range) nadir platelet was 74(29-194) 
103cell/µL. The temporal predominant serotype was DENV-3 (29.3%), followed by DENV-2 (24.4%), 
DENV-1 (13.6%), and DENV-4 (2.4%). The study found concurrent DENV infection. Diagnosis of DF was 
almost equal with DHF. Level of TNF-α found 3 times higher in DHF than DF patients. 
1 Introduction  
Dengue virus (DENV) infection has become a major 
threat and serious public health problem worldwide. 
More than 2.5 billion people in tropical and sub-tropical 
countries are at high risk to get DENV infection [1]. 
The prevalence of DENV infection has been reported 
to be increase 3 times greater than the WHO prediction, 
recently [2]. The annual DENV case has been reported 
as high as 390 million cases per year with 96 million 
symptomatic cases [3]. Mortality rate of DENV may 
exceed 5% in particular population such as too young 
cases, elderly, pregnant, immune compromise or people 
with pre-existing illnesses [3].  
Dengue virus is a RNA virus belong to genus 
Flavivirus, consist of 4 antigenically distinct serotype, 
DENV-1 through DENV-4 [4]. Infection by one DENV 
serotype confers life-long immunity, and partial non-
neutralizing antibody to the others serotype [5], [6]. The 
genome of the DENV encode 3 structural proteins and 7 
non-structural proteins which involved in virus 
replication or DENV pathogenesis. Role of non-
structural protein (NS)-1 in dengue severity has been 
evaluated elsewhere [7], [9].  
Clinical manifestation of DENV vary mostly mild 
asymptomatic, symptomatic to the life threatening shock 
syndrome. Traditionally, the DENV infection classified 
as Dengue Fever (DF), Dengue Hemorrhagic Fever and 
Dengue Shock Syndrome (DSS) [10]. A key features to 
differentiate DF and DHF is a plasma leakage, in which 
severe plasma leakage lead to hypovolemic shock (DSS) 
[11].  
The pathogenesis of severe dengue is not fully 
elucidated, although studies of this have been conducted 
extensively. Nowadays, dengue immunopathogenesis 
included antibody enhancement theory (ADE), massive 
activation of T-cell memories, and original antigenic sin 
[12].  
Excessive productions of cytokines in DENV are 
proposed to induce endothelial instability and leakage. 
These condition termed cytokine storm has been 
associated with DENV severity elsewhere and pro-
inflammatory cytokine such as Tumour Necrosis Factor-
α (TNF-α), Interleukin (IL-1α), IL-6, IL-8, IL-12,  
macrophage inhibitory protein-1-alpha (MIP-1α), MIP-
1β, RANTES, Interferon gamma-induced protein 10 
(IP10), Interferon gamma (IFN-γ) [13], TGF-β [14], 
sVCAM [15], sICAM and many other soluble proteins 
has been found to be increase in DHF patient. 
TNF-α is one of the inflammatory cytokine produced 
by mononuclear cells in response to an infection. This 
cytokine has been known a pivotal role in generating 
cytokines cascade orchestra in many inflammatory 
diseases. TNF-α also increases mediators through 
activation of lipid signal transduction such as 
prostaglandins and platelet activating factor [16]. 
Bali has become the most popular tourism destination 
in the world. Dengue infection has been found 
hyperendemic in Bali since all four DENV serotype 
circulate in Bali [17]. Travellers visiting Bali are at risk 
to get DENV infection during visiting Bali. Hence, a 
prospective study has been conducted in order to 
evaluate the profile one of the pro-inflammatory 
cytokine, TNF-α, among travellers infected with DENV 
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2 Material and methods 
2.1 Patient Selection 
This study was a cross-sectional study on 41 serum of 
travellers infected with dengue virus that were admitted 
to the Kasih Ibu Hospital, Bali. The diagnosis was made 
on anamnesis, clinical findings, complete blood count 
and NS1 test. This study was approved by ethical 
committee of Universitas Udayana, Denpasar (Document 
number: 282/UN.14.2/KEP?2017).  
2.2 Laboratory Assay 
We obtain acute sera up to day 5 of onset of fever for 
detection of NS1 dengue antigen and DENV serotype 
detection as the definition dengue criteria. Detection of 
NS1 antigen was performed using the SD Bioline NS1 
Rapid Test (Alere, Australia). Diagnosis of dengue was 
based on NS1 positive or detection of RNA dengue by 
reverse transcriptase PCR and Simplexa Real Time 
PCR. 
Diagnosis of dengue hemorrhagic fever (DHF) was 
based on hematocrit difference more than 20% from 
acute to convalescence sera or the finding of pleural 
effusion or ascites on physical examinations. Grading of 
DHF was based on WHO criteria [18]. Status of DENV 
infection wether primary or secondary infection was 
based on the positivity of IgG anti dengue before the day 
7th of illness. Serum level of TNF-α were quantified 
using the Biolegend commercial ELISA assay kits, 
according to manufacturer`s protocols. The patient`s sera 
stored at -80°C at Universitas Warmadewa until testing. 
2.3 Statistical Methods 
We analysed the TNF-α level among DF and DHF 
patients using SPSS 21.0 version. 
3 Result 
From the 41 of the total subjects in this study, almost a 
half of them included in the 31 - 45 age groups and 
majority of the sample were female (Table 1). The 
median age of the samples was 29 years old (range 15.4-
73.1). 
Table 1. Characteristic of Samples. 
Characteristic n (%) 
Age Group (year) 
  
 
0 – 15 1 (2.4) 
 
16 – 30 19 (46.3) 
 
31 – 45 13 (31.7) 
 
46 – 60 6 (14.6) 
 




Male 16 (39.0) 
 
Female 25 (61.0) 
Of 41 samples, NS1 antigen was positive in 40 
(97.56%) and PCR was able to detect the DENV in 32 
(78.05%) of the samples. Table 2 presented the 
laboratory finding of the samples. The lowest leucocyte 
and platelet number was found as low as 1 x 109cell/µL 
and 29 x 109cell/µL, respectively. 
Table 2. Laboratory finding. 








AST (median/range)  44(14-500) 














There was almost equal finding of the DENV-2 and 
DENV-3 on the study. One case found to be infected 
with DENV-2 plus DENV-4 (concurrent dengue 
infection) with relatively mild dengue manifestation or 
having DF as the diagnosis. Table 3 showed that ninety 
percent of the subjects diagnosed with DF and the mean 
of TNF-α concentration in DHF patients were three 
times higher than DF patients.  
Table 3. Level of TNF-α in DF and DHF Patients. 
Diagnosis 
n (%) TNF-α (X ± S.D) 
  
DF 37 (90.2) 8.32 ± 12.36 
DHF 4 (9.8) 28.39 ± 30.17 
The big four nationality of the samples was 
Germany, Russian, Dutch and Swedish, counted for 
9(22%), 6(14.6%), 5(12.2%) and 4(9.8%), respectively. 
The study define DENV infection as a secondary 
infection based on the positivity of IgG anti Dengue on 
the convalescence sera (on day 7 of DENV).  The study 
found primary DENV infection was almost equal with 
secondary DENV infection (51.2 versus 48.8%). 
Bleeding was found as high as 5/41 (12.20%) with 
vaginal bleeding as the most bleeding. 
4 Discussion 
Dengue is hyper-endemic in Indonesia and all 33 
provinces of Indonesia have reported the incidence of 
dengue [19]. The intensive labor flow and travelers 
factors in Bali have been reported to contribute to the 
spread of DENV infection [20]. Previous reports 
indicated the hyperendemic transmission of all four 
DENV serotypes in Bali where circulating DENVs 
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included dominant local strains, suggesting that Bali is a 
melting pot of substantial DENV diversity and serve as a 
hub for dengue transmission and mixing [17], [21].  
The most predominant serotype detected was DENV-
3. This finding is similar with the result from local 
Balinese in 2015 where DENV-3 was predominant [17]. 
Our result was in contrast with data reported by Ernst, et 
al [21]. Which showed the predominance DENV found 
was DENV-2 in Australian travellers visiting Bali in 
2010. The predominance of DENV-2 was also reported 
in other city in Indonesia in 2012 [22].  
 In term of DENV diagnosis, the study found DF as 
the majority diagnosis.  Dengue fever is the mild form of 
DENV infection in which DF mostly found in the 
primary DENV infection. Since the travellers are from 
non-endemic country, it is reliable if the most clinical 
manifestation is mild dengue or manifest as DF. The 
local study also found that DF is the predominance 
clinical diagnosis among the local patients [22]. In term 
of the infection status, the majority of DENV infection 
was of primary infection. All the samples were collected 
from adult patients and since the travellers came from 
countries where dengue is not generally present (Figure 
1), we may presume that they have contracted dengue for 
the first time during their visit to Bali.  
 
Fig. 1. Nationality of the samples. 
The level of TNF-α in DHF sample is 3 times higher 
than DF samples. Since the number of DHF is not met 
the statistical analysis stipulation, this difference maybe 
is not suitable for generalization. Previous study reveals 
an increasing of TNF-α level during acute phase of 
DENV infection. [23] In contrast with other study that 
found no difference of TNF-α level between DHF and 
DF patients or also DSS.  
The study limitation is the low sample size, study 
design and statistical analysis. Since the study is still on-
going, further samples recruitment will allow the best 
study result. 
5 Conclusion 
There is a difference of the TNF-α level in DF and DHF 
samples. The difference of TNF-α between DF and DHF 
need further statistical analysis to generalized to the 
population. 
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